As we wait for the Canadian courts to repeat the process that made cannabis legal after decades in purgatory, some companies aren’t waiting around for their chance to claim a piece of the upcoming shroomaceuticals market.
-
-
Yield Growth Corp (BOSS.C) subsidiary takes on 18% of shroom clinical trial outfit
CBD product developer/retailer Yield Growth Corp (BOSS.C) has announced it has agreed to acquire 18% of Translational Life Sciences, a company that “aims to develop proprietary formulations using restricted substances to focus on unmet medical needs in opioid dependence, psychotic illness, pain management and traumatic brain injury, including concussion.”
-
Absolem: Laying the groundwork for the big mushroom shift to come
50 years I’ve been bumbling around this planet, and the best damn weekend I’ve had on it to date occurred recently, under the influence of mushrooms.
-
Absolem Health signs a mushroom extraction deal
On November 26, 2019 Absolem Health announced that it has entered into an L.O.I with Arev Brands (AREV.C) to “develop and produce mushroom extracts”, and potentially to collaborate to sell “mushroom-based products.”
-
How MAPS broke from the pack of profit-oriented psychedelic industry
With a stated mission of patients over profits, the Multidisciplinary Association for Psychedelic Studies (MAPS) is an outlier within the growing psychedelic treatment industry.
